US Exchange Filings

Aprea Therapeutics Reports Interim APR-1051 Phase 1 Cancer Trial Results

Aprea Therapeutics reported two partial responses in patients with PPP2R1A-mutated uterine cancers in its early APR-1051 trial, alongside evidence of target engagement. The findings support continued dose optimization and expansion into selected ovarian and uterine cancer groups.

Aprea Therapeutics reported interim results from its first-in-human Phase 1 trial of APR-1051, an oral experimental WEE1 inhibitor being tested in people with advanced solid tumors. The early data include two partial responses in patients with PPP2R1A-mutated uterine cancers, evidence that the drug is hitting its intended target, and initial safety findings. The company plans to continue dose optimization and expand enrollment in selected ovarian and uterine cancer groups.

Aprea also updated its corporate presentation.

Key trial details

  • 56 patients had received APR-1051 across dose levels by the November 1, 2026 data cutoff. Of those, 43 could be evaluated for tumor response; 13 had not yet had their first on-treatment scan.
  • Two patients with PPP2R1A-mutated uterine cancers had partial responses: one confirmed and one not yet confirmed. The confirmed response was in a patient with uterine carcinosarcoma treated at 220 mg; the patient remained on treatment more than 10 months after the cutoff.
  • Sixteen patients had stable disease as their best recorded response. Five had maintained stable disease for at least four months.
  • Target-engagement results were positive across multiple dose levels. In skin-biopsy samples, 21 of 25 evaluable patients had a reduction of at least 50% in pCDK1-Y15, a marker used to assess WEE1 inhibition.
  • One dose-limiting toxicity was reported among the 56 treated patients: elevated liver enzymes in a patient with known liver metastases who received 50 mg.
  • Four patients (7%) had severe neutrophil-count decreases, all at the 300 mg dose level; one case was serious. No febrile neutropenia was reported. Two patients (4%) experienced serious Grade 3 pneumonitis.
  • Aprea said the safety findings, target-engagement data and longer follow-up support continued dose optimization and once-daily dosing. Its release says pharmacokinetic data support once-daily administration but provides no specific pharmacokinetic measurements.
  • The company plans to enroll at least 50 patients in focused groups: uterine serous carcinoma and cyclin E-overexpressing, platinum-resistant ovarian cancer. Dose escalation and backfill enrollment are continuing, with completion expected in the second quarter of 2027.
  • The interim results were scheduled for presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona.

What the results show

The trial remains in an early dose-finding stage, and the response numbers come from a small group of evaluable patients. The findings provide initial evidence of activity and target engagement, but do not establish how effective APR-1051 is across either cancer group. The planned focused enrollment is intended to build evidence in the tumor types Aprea considers most relevant for WEE1 inhibition.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.